Marjorie A. Speers, Ph.D., executive director of Clinical Research Pathways, recently submitted comments on FDA draft guidance on enhancing the diversity of clinical trial populations. The comments reflect Clinical Research Pathways’ commitment to enrolling more minority patients in clinical research. If the demographic mix of clinical trial participants mirrors that of the population as a whole, data on new medicines will reflect the effectiveness and potential side effects for all groups—and all groups will benefit.

 [Download PDF]